Detalhe da pesquisa
1.
Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Cell
; 175(1): 186-199.e19, 2018 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30220457
2.
SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models.
Acta Pharmacol Sin
; 39(2): 243-250, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28905937
3.
Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R.
Acta Pharmacol Sin
; 39(11): 1768-1776, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29968849
4.
Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.
Acta Pharmacol Sin
; 38(4): 551-560, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28112184
5.
Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
Acta Pharmacol Sin
; 38(7): 1038-1047, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28414200
6.
HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
Int J Cancer
; 135(10): 2462-74, 2014 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24706460
7.
Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.
Eur J Med Chem
; 259: 115709, 2023 Nov 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37567056
8.
Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.
EMBO Mol Med
; 15(3): e16235, 2023 03 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652375
9.
Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer.
Cell Death Dis
; 13(8): 748, 2022 08 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36038549
10.
[Evaluation of right ventricle function by tissue Doppler imaging in patients with acute organophosphate poisoning].
Zhonghua Yi Xue Za Zhi
; 90(29): 2052-5, 2010 Aug 03.
Artigo
em Chinês
| MEDLINE | ID: mdl-21029643
11.
Author Correction: G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin.
Nat Commun
; 11(1): 3789, 2020 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32709895
12.
[Application of fluorescence in situ hybridization in prenatal diagnosis of complex chromosomal abnormalities].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi
; 26(5): 529-32, 2009 Oct.
Artigo
em Chinês
| MEDLINE | ID: mdl-19806574
13.
[Molecular and cytogenetic study on 18 cases of amenorrhea: the use of fluorescence in situ hybridization and high resolution-comparative genomic hybridization].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi
; 24(3): 256-60, 2007 Jun.
Artigo
em Chinês
| MEDLINE | ID: mdl-17557232
14.
G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin.
Nat Commun
; 8(1): 274, 2017 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-28819251
15.
Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Cancer Lett
; 386: 47-56, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27847302
16.
Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution.
Oncotarget
; 8(3): 4156-4168, 2017 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27926532
17.
c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.
Cancer Res
; 75(21): 4548-59, 2015 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26483207